Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.
593 results about "Protein.monoclonal" patented technology
Filter
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Monoclonal gammopathies are conditions in which abnormal proteins are found in the blood. These proteins grow from a small number of plasma cells in the bone marrow.
The invention provides a kit for simultaneously detecting RBP in a urine sample and a serum sample. The kit comprises a reagent R1 and a reagent R2, the reagent R1 is a polymerbuffer solution having an agglomeration promotion effect, the reagent R2 is a buffer solution containing a latex-antibody crosslink, and the latex-antibody crosslink comprises anti-RBP polyclonal antibody marked large latex particles and anti-RBP monoclonal antibody marked small latex particles. The kit which adopts a composite monoclonal and polyclonal antibody sensitized latex enhanced immune detection method has the advantages of simultaneous satisfying of the requirements comprising good specificity, high sensitivity and wide linear range, small antibody application amount, and cost reduction, and can be simultaneously used for the clinic detection of the RBP in human blood and urine.
The invention provides a porcine reproductive and respiratory syndrome virus double-antibody sandwich ELISA kit. The kit comprises: an elisa plate coated with PRRSV N proteinmonoclonalantibody, an enzyme labeling PRRSV N proteinmonoclonalantibody, lysis solution and the like. A capture antibody and a detection antibody are respectively aimed at antigenic determinants with different N proteins.The kit provides a reliable means for quick detection of clinical PRRSV antigen. The kit can detects that blood serum only contains 0.2 TCID50 highly pathogenic PRRSV JXwn06 strain (non-highly pathogenic strain can be also be detected). Through detecting clinically collected 80 blood serum samples, compared with RT-PCR result, the specificity of the method is 88 percent, the sensitiveness is 90 percent and the coincidence rate of the specificity and the sensitiveness are 88.8 percent. The kit is convenient for operation, low in use cost, good repetitiveness and suitable for wide promotion andapplication.
The invention relates to a competitive ELISA method based on a foot-and-mouth disease A type VP1 protein and its monoclonalantibody, also relates to a preparation method of the foot-and-mouth disease A type VP1 protein, and a preparation method of the monoclonalantibody of the foot-and-mouth disease A type VP1 protein, and belongs to the technical field of animal immunological detection. In the invention, a primer pair C1 and C2 and a primer pair E1 and E2 are amplified to obtain a gene sequence of the foot-and-mouth disease A type VP1 protein, the foot-and-mouth disease A type VP1 protein is obtained by constructing an expression plasmid, introducing the expression plasmid into a prokaryotic expression host and carrying out inducible purification, the foot-and-mouth disease A type VP1 protein monoclonalantibody is obtained by treating the foot-and-mouth disease A type VP1 protein as an antigen through a hybridomas technology, and the competitive ELISA method used for detecting a foot-and-mouth disease A type antibody is established based on the foot-and-mouth disease A type VP1 protein and its monoclonal antibody. The detection method has a strong specificity and a good stability, and can be used for detecting a foot-and-mouth disease A type serum antibody. By comparing a result obtained through the detection method with a liquid phase blocking ELISA kit, the coincidence rate is 95.8%.
The invention discloses a hybridoma cell capable of secreting an anti-novel coronavirus (SARS-COV-2) N proteinmonoclonalantibody, a monoclonalantibody and anapplication. The invention provides a hybridoma cell strain N-3G3, wherein the preservation number of strain is CCTCC NO: C202075. The invention also protects the monoclonalantibody secreted by the hybridoma cell strain N-3G3. The antibodywith high sensitivity and high specificity is the key to the development and implementation of an antigen detection technology. The specific antibody of the N protein of the SARS-CoV-2 is obtained onthe basis of a monoclonal antibody technology, and an SARS-COV-2 detection test strip is prepared from the N protein of the SARS-CoV-2. When the test strip provided by the invention is used for detecting the SARS-CoV-2, the operation is simple, the sensitivity is high, the specificity is strong, and the rapid monitoring and prevention of the SARS-COV-2 can be realized.
The invention discloses a fluorescence quantitative immunochromatography test paper strip for fast detecting zika virus NS1 protein and a manufacturing method thereof. The test paper strip comprises a bottom plate, wherein a sample pad, a combination pad, a covering film and water suction paper are sequentially arranged on the bottom plate and are in sequential lap joint; a fluorescent microsphere marked zika NS1 proteinmonoclonalantibody and a fluorescent microsphere marked goat anti-chicken antibody are arranged on the combination pad; a zika NS1 proteinmonoclonalantibody with different epitope from the fluorescent microsphere marked zika NS1 protein monoclonal antibody on the combination pad covers a detection region of the covering film; a chicken IgY antibody covers a quality control region. The manufacturing method comprises the following steps of fluorescent microsphere cleaning and activation, fluorescent microsphere marked antibody preparation, fluorescent marked antibody combination pad preparation, covering film preparation and test paper strip assembly. The manufactured test paper strip can be used for fast, specially and precisely detecting the zika virus NS1 protein; the fast quantitative detection in field can be realized.
The invention discloses a preparation method for a PCV-II Cap proteinmonoclonalantibody, an antibody and application. The invention adopts ultracentrifuged and purified PCV-II as an immunogen to immunize a BALB / c mouse by the conventional method, takes spleen cells of the immunized BALB / c mouse to fuse with SP2 / 0 cells, obtains two strains of hybridoma cells secreting the PCV2-Cap proteinmonoclonal antibodies by indirect ELISA screening, respectively names the two strains of hybridoma cells as 8-60 and 10-48, identifies biological characteristics of the two strains 8-60 and 10-48, and usesthe two strains 8-60 and 10-48 as the first antibodies to establish an indirect immunofluorescence diagnostic method. The result of the indirect immunofluorescence diagnostic method is basically consistent with that of the PCR diagnostic method, and the positive and negative coincidence rates are respectively 93.75 percent and 100 percent so as to provide reference for preventing and treating theporcine circovirusdisease.
The present invention provides matched antibody pairs for the specific detection of one or more of the four dengue virus serotypes in a biological sample that may contain one or more of such dengue virus serotypes. Each matched antibody pair is capable of detecting not more than one serotype of dengue virus NS1 protein that may be present in the sample and will not cross react with other serotypes that may be present in the sample. Multiple matched pairs may be used to detect one or more dengue virus serotypes that may be present in a sample. Such matched pair antibodies, facilitate the development of confirmatory in vitro diagnostic tests such as sandwich immunoassays, that detect and distinguish the presence of one or more dengue virus serotypes in a biological sample, preferably a sample derived from human subject. The invention also provides kits comprising the matched antibody pairs of the invention and methods for using the kits for immunoassays for the specific detection of one or more serotypes of dengue virus in a patient population. The present invention also provides monoclonal antibodies specific for the NS1 protein of dengue virus and therapeutic compositions and methods for treating dengue virus infection.
The invention relates to a PCV1 and PCV2 differential detection paper card which can be used for rapid identification and detection of pig PCV2 infection. The reaction reagent carrier adsorption layer comprises a fiber layer, a gold-labeled fiber layer, a cellulose film and an absorbent-material layer; the gold-labeled fiber layer is a gold-labeled glass wool adsorbing colloidal gold-labeled anti-capsidproteinmonoclonal antibodies which can identify PCV1 and PCV2 common epitope, and the cellulose film is a nitrocellulose film which is orderly printed with a detection trace T1, a detection trace T2 and a control trace C; the detection trace T1 is a strip-shaped PVC1 detection trace printed and produced by monoclonalantibody solution which can identify PCV1-typed specific epitope; and T2is a strip-shaped PVC detection trace printed and produced by anti-capsidproteinmonoclonalantibody solution which can identify PCV1 and PCV2 common epitope, and the control trace C is a strip-shaped control trace which is printed and produced by anti-mouse IgG polyclonal antibody solution. The paper card has the advantages of strong specificity, high sensitivity, convenience and speediness andintuitive test result, and can be easily promoted for application in the production practice.
The invention discloses a porcine circovirus type 2 antigen capture ELISA kit. The kit internally comprises an enzyme labeled monoclonalantibody which is secreted by a hybridoma cell strain with the preservation number of CGMCC NO.10205. The invention also discloses a capture ELISA method for rapidly detecting the porcine circovirus type 2 and established by utilizing the monoclonalantibody. A porcine circovirus type 2 polyclonal antibody and a porcine circovirus type 2 cap proteinmonoclonal antibody respectively act as a capture antibody and a detecting antibody. The method can be used for detecting multiple gene type PCV2 viruses; the detection sensibility is 400 TICD50 / ml; the porcine circovirus type 2 has no crossed reaction with other swine viruses, and the toxic value determination method coincidence rate is 88%. The result shows that the method has the advantages of operation simplicity, good specificity, high sensitiveness, short time consumption and the like, can be used for estimating the toxic value of viruses, and can conveniently and rapidly control the quality of PCV2 inactivated vaccine semi-finished products.
The invention discloses an immune-fluorescence test strip component for rapidly detecting C-reactive protein quantitatively, a detection card component produced by the same and a method for preparing the same. The test strip component comprises a test strip and a platinumporphyrin marked specific antibody independently packed. The test strip comprises a bottom lining, a water absorption pad, coating analysis film and a sample pad. The coating analysis film is provided with a detection line and a quality control line, a specific antibody coated by the detection line is a C-reactive protein resistance monoclonalantibody, and a specific antibody coated by the quality control line is a rabbit intravenous gamma globulin (IgG) antibody; the detection card component comprises a test strip, a card box composed of a cover plate and a back plate and a latinum porphyrin marked specific antibody independently packed. The test strip component for detecting C-reactive protein in body fluid has the advantages of being simple in operation, rapid, sensitive, good in specificity and the like, and having good clinical application prospect.
The invention relates to immunochromatographic test paper for detecting novel coronavirus SARS-CoV-2. The test paper comprises a substrate, and a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad which are arranged on the substrate and are sequentially and fixedly adhered to the substrate along the flowing direction of a to-be-detected liquid sample, the substrateis a PVC plate. The sample pad is coated with a biotin labeled anti-SARS-CoV-2N proteinmonoclonalantibody and biotin labeled angiotensin converting enzyme 2 (ACE2), the combination pad is coated with avidin crosslinked colloidal gold, the nitrocellulose membrane is provided with a detection line and a quality control line, the detection line is coated with an anti-SARS-CoV-2M protein monoclonalantibody, and the quality control line is coated with goat anti-mouse IgG. The immunochromatographic test paper provided by the invention achieves high-sensitivity, high-specificity, high-speed and convenient-to-operate detection, and can be applied to large-scale rapid screening of people in primary hospitals and communities.